Missing data sensitivity analysis for recurrent event data using controlled imputation

Pharmaceutical Statistics

Volumn 13, Issue 4, 2014, Pages 258-264

  Keene, Oliver N ^a   Roger, James H ^b   Hartley, Benjamin F ^a   Kenward, Michael G ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

exacerbation; missing; MNAR; multiple imputation; recurrent event; sensitivity

Indexed keywords

MEPOLIZUMAB;

ANALYTIC METHOD; ARTICLE; ASTHMA; BINOMIAL DISTRIBUTION; CONTROLLED IMPUTATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; MISSING DATA SENSITIVITY ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT EVENT DATA; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; PROCEDURES; STATISTICAL MODEL;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL;

EID: 84904504679     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1624     Document Type: Article

References (24)

1. National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press: Washington, DC, 2010. Available at: http://www.nap.edu/search/?term=12955 (accessed 7 June 2014).
2. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan J, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H,. The prevention and treatment of missing data in clinical trials. New England Journal of Medicine 2012; 367 (14): 1355-1360.
3. Carpenter JR, Roger JH, Kenward MG,. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple Imputation. Journal of Biopharmaceutical Statistics 2013; 23: 1352-1371.
4. Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G,. A structured approach to choosing estimands and estimators in longitudinal clinical trials. Pharmaceutical Statistics 2012; 11: 456-461.
5. Mallinckrodt C, Roger J, Chuang-Stein C, Molenberghs G, Lane PW, O'Kelly M, Ratitch B, Xu L, Gilbert S, Mehrotra D, Wolfinger R, Thijs H,. Missing data: turning guidance into action. Statistics in Biopharmaceutical Research 2013; 5 (4): 369-382.
6. Keene ON,. Intent-to-treat analysis in the presence of off-treatment or missing data. Pharmaceutical Statistics 2011; 10: 191-195.
7. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG,. For the CONSORT Group. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 2010; 340: c869.
8. Altman DG,. Missing outcomes in randomised trials: addressing the dilemma. Open Med 2009; 3 (2): 51-53.
9. Committee for Medical Products for Human Use. Guideline on missing data in confirmatory clinical trials. European Medicines Evaluation Agency: London, September 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/09/WC500096793.pdf (accessed 7 June 2014).
10. Little RJA, Yau L,. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52: 471-483.
11. Mallinckrodt CH,. Preventing and Treating Missing Data in Longitudinal Clinical Trials. Cambridge University Press: Cambridge, UK, 2013.
12. O'Kelly M, Ratitch B,. Clinical Trials with Missing Data: A Guide for Practitioners. Wiley: Chichester, UK, 2014.
13. Keene ON, Calverley PMA, Jones PW, Vestbo J, Anderson JA,. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal 2008; 32: 17-24.
14. Keene ON, Jones MRK, Lane PW, Anderson J,. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharmaceutical Statistics 2007; 6: 89-97.
15. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P,. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet 2012; 380 (9842): 651-659.
16. Barnard J, Rubin D,. Small-sample degrees of freedom with multiple imputation. Biometrika 1999; 86: 948-955.
17. Ratitch B, O'Kelly M, Tosiello R,. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharmaceutical Statistics 2013; 12: 337-347.
18. Meng X-L,. Multiple-imputation inferences with uncongenial sources of input. Statistical Science 1994; 9: 538-558.
19. Kenward MG, Molenberghs G,. Last observation carried forward: a crystal ball? Journal of Biopharmaceutical Statistics 2008; 19: 872-888.
20. Carpenter JC, Kenward MG, Evans S, White IR,. Last observation carry-forward and last observation analysis. Letter to the Editor. Statistics in Medicine 2004; 23: 3241-3244.
21. Molnar FJ, Hutton B, Fergusson G,. Does analysis using 'last observation carried forward' introduce bias in dementia research? Canadian Medical Association Journal 2008; 179: 751-753.
22. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP,. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal 2008; 42: 303-319.
23. Hughes S, Harris J, Flack N, Cuffe RL,. The statistician's role in the prevention of missing data. Pharmaceutical Statistics 2012; 11: 410-416.
24. Aregay M, Shkedy Z, Molenberghs G,. A hierarchical Bayesian approach for the analysis of longitudinal count data with overdispersion: a simulation study. Computational Statistics & Data Analysis 2013; 57: 233-245.